EQT-backed Dechra acquires Gallant Pet
The San Diego company develops cell therapies for companion animals. Dechra completed the acquisition on November 17.
- Target
- Gallant Pet
- Acquirer
- Dechra
- Backed by
- EQT
- Status
- Completed
- Announced
- Closed
Dechra agreed to acquire Gallant Pet on November 9 and completed the purchase on November 17. Gallant is an animal health biotechnology company developing ready-to-use regenerative therapies for pets. Terms were confidential.
Gallant was founded in 2018 and operates a manufacturing facility in San Diego, California. Dechra said the deal expands its veterinary specialty care business into regenerative medicine. Sidley represented Dechra.
EQT lists Dechra as a current portfolio company. EQT and co-investors took Dechra private in 2024.
Background
- Business
- Companion animal therapeutics developer
- Deal type
- Add-on
- Headquarters
- San Diego, California
- Advisers
- Sidley Austin legal adviser to Dechra
Sources
- GallantNov 9, 2026
- DechraNov 9, 2026
- DechraCompletion confirmation · Nov 17, 2026
- Sidley AustinNov 18, 2026
- EQT
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.
Follow coverage. Copy a feed link into your feed reader.